United States Drug Patent 9,271,975: Claim Scope, Orange Book Position, Generic Risk, and Netupitant-Palonosetron Patent Landscape

U.S. Patent No. 9,271,975 protects clinical use of the fixed-dose oral combination of netupitant and palonosetron, marketed as Akynzeo, when administered no more than one hour before moderately or highly emetogenic chemotherapy. Its claims focus on measured antiemetic outcomes during acute, delayed, and overall treatment phases rather than on the composition alone.

The patent’s commercial importance is concentrated in the 300 mg netupitant/0.5 mg palonosetron hydrochloride dose and in chemotherapy regimens such as carboplatin, cisplatin, anthracycline-based therapy, oxaliplatin, and cyclophosphamide. A generic product that copies the Akynzeo composition and carries labeling directing administration before emetogenic chemotherapy could face induced-infringement exposure through the patent’s method-of-use claims.

What does U.S. Patent 9,271,975 protect?

U.S. Patent 9,271,975 protects methods of preventing chemotherapy-induced emesis and nausea using oral netupitant plus palonosetron. The patent does not broadly claim every netupitant-palonosetron product. It requires a specific administration context and, in most claims, a specified clinical result.

Element	Requirement under claims 1-12
Patient	Human subject in need of antiemetic treatment
Dosage form	Oral dosage form
Active ingredients	Netupitant and palonosetron, or pharmaceutically acceptable salts
Timing	No more than one hour before chemotherapy
Chemotherapy	Moderately or highly emetogenic chemotherapy
Outcomes	No emesis, no significant nausea, or no nausea
Measurement window	Acute: at least about 24 hours; delayed: about 24-120 hours; overall: at least about 120 hours
Key dose	About 300 mg netupitant and about 0.5 mg palonosetron hydrochloride
Priority chemotherapy example	Carboplatin
Patent	U.S. 9,271,975 B2

The patent is therefore a treatment-outcome patent with a product-and-regimen limitation. It is narrower than a composition patent covering all dosage forms and ratios of the two active ingredients.

How are claims 1 through 7 structured?

Claims 1 through 7 are the principal independent method claims. They divide protection by clinical endpoint and treatment phase.

Claims 1-3: prevention of emesis

Claim 1 covers prevention of emesis during the overall phase, measured over at least approximately 120 hours after chemotherapy begins.

Claim 2 covers the acute phase, measured during at least approximately the first 24 hours.

Claim 3 covers the delayed phase, measured from approximately 24 through 120 hours.

These claims require that no emetic episode occur during the applicable period. The claim language is outcome-based. Administration of the two drugs alone is not enough if the claimed no-emesis result is not obtained under the claim’s measurement standard.

Claims 4-6: prevention of significant nausea

Claims 4 through 6 use a visual analog scale, or VAS, to define the clinical result.

Claim	Phase	Required outcome
4	Overall	Maximum VAS below 25 mm over at least about 120 hours
5	Acute	Maximum VAS below 25 mm over at least about 24 hours
6	Delayed	Maximum VAS below 25 mm during about 24-120 hours

These claims do not require complete absence of nausea. They require the maximum VAS score to remain below 25 mm during the specified interval.

Claim 7: prevention of any material nausea

Claim 7 is narrower on the nausea threshold. It requires a maximum VAS below 5 mm during the delayed phase.

The distinction between claims 6 and 7 is commercially relevant. A regimen may satisfy the below-25-mm threshold in claim 6 without satisfying the more demanding below-5-mm threshold in claim 7.

What does claim 8 add to the patent?

Claim 8 narrows claim 1 to the fixed-dose combination containing approximately:

300 mg netupitant; and
0.5 mg palonosetron hydrochloride, measured on the basis of palonosetron free-base weight.

This is the dosage corresponding to Akynzeo’s approved oral capsule strength. The claim is important because a generic product matching the approved strength would fall directly within the express dose limitation if the remaining timing, chemotherapy, and outcome limitations are met.

The claim does not independently protect the capsule’s excipient system, release profile, manufacturing process, or physical form. Those matters would require separate composition, formulation, or process claims.

Which chemotherapy regimens fall within claims 9 through 12?

Claims 9 through 12 expand the method claims across defined chemotherapy categories.

Claim 9: carboplatin

Claim 9 specifically covers the method of claim 1 when the chemotherapy includes carboplatin. Carboplatin is classified as moderately emetogenic in the claim set, although the commercial importance of the claim is high because carboplatin-based regimens are common in ovarian, lung, breast, and other cancers.

Claims 10 and 11: highly and moderately emetogenic chemotherapy

Claim 10 identifies highly emetogenic agents, including:

Carmustine
Cisplatin
Cyclophosphamide at 1,500 mg/m² or higher
Dacarbazine
Dactinomycin
Mechlorethamine
Streptozotocin
Combinations of those agents

Claim 11 identifies moderately emetogenic agents, including:

Carboplatin
Cyclophosphamide below 1,500 mg/m²
Cytarabine above 1 mg/m²
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
Combinations of those agents

Claim 12 consolidates the listed moderately and highly emetogenic agents into a broader chemotherapy group.

The dosage threshold for cyclophosphamide is significant. The same active ingredient is assigned to different claim categories depending on dose.

What are the principal claim limitations for infringement?

A potentially infringing use must satisfy all limitations of at least one asserted claim. The key limitations are:

An oral dosage form must be used.
Both netupitant and palonosetron must be present.
The product must be administered no more than one hour before chemotherapy.
The chemotherapy must be moderately or highly emetogenic as defined by the claim or applicable clinical classification.
The claimed clinical endpoint must occur during the specified period.
For claim 8, the product must contain approximately 300 mg netupitant and 0.5 mg palonosetron hydrochloride.

A product containing the two active ingredients but administered several hours before chemotherapy would not satisfy the express timing limitation. An intravenous product would not satisfy the oral dosage-form limitation. A product used for postoperative nausea, radiation-induced nausea, or non-chemotherapy-related nausea would not satisfy the chemotherapy limitation.

The outcome limitations create a potential evidentiary issue. In a direct-use case, the patent holder would generally need to establish that the claimed method was performed, including the relevant timing and treatment context. In an induced-infringement case, a generic label can be important evidence if it instructs physicians or patients to administer the product before moderately or highly emetogenic chemotherapy.

When does U.S. Patent 9,271,975 expire?

The patent has a projected statutory expiration in December 2030 based on its underlying priority and U.S. patent-term calculation. The exact terminal date depends on the patent’s recorded filing history, patent-term adjustment, terminal disclaimers, and any applicable extension.

Milestone	Date or status
U.S. patent	9,271,975
Grant date	March 1, 2016
Technology	Netupitant/palonosetron antiemetic treatment
Projected ordinary expiration	December 2030
Patent-term extension	No extension is established in the claim information supplied
Commercial product	Akynzeo
FDA approval	October 10, 2014

The patent’s expiration is later than Akynzeo’s regulatory exclusivity period. FDA marketing exclusivity and patent exclusivity operate independently. A loss of regulatory exclusivity does not eliminate an unexpired patent.

What is the FDA and Orange Book status of Akynzeo?

Akynzeo is FDA-approved as an oral fixed-dose combination of netupitant and palonosetron for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy. The product is associated with NDA 205718.[1]

The approved dose is one capsule containing 300 mg netupitant and 0.5 mg palonosetron. FDA labeling instructs administration approximately one hour before chemotherapy, together with a corticosteroid regimen specified in the prescribing information.[1]

U.S. Patent 9,271,975 is part of the patent estate relevant to Akynzeo’s antiemetic use. Orange Book status must be evaluated together with any other patents listed for NDA 205718, including composition, formulation, dosage, or method-of-use patents.[2]

Regulatory exclusivity timeline

Event	Date
FDA approval of Akynzeo	October 10, 2014
Initial regulatory exclusivity period	Expired before the patent term
Expected patent-protected period under U.S. 9,271,975	Through approximately December 2030
Generic pathway after patent expiry	ANDA, subject to all listed patents and exclusivities

A generic applicant may submit an ANDA before patent expiry, but commercial launch depends on the certifications made for each Orange Book-listed patent and the outcome of any patent litigation.

What Paragraph IV risks exist for a generic Akynzeo product?

A generic applicant seeking approval before expiration could use one or more of the following certifications:

Paragraph I: no patent information has been filed.
Paragraph II: the listed patent has expired.
Paragraph III: the applicant will wait until patent expiration.
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.
Section viii statement: the applicant will omit a patented method of use from its labeling.

For U.S. Patent 9,271,975, a Paragraph IV strategy could challenge:

Written description or enablement for the clinical-result limitations.
Definiteness of terms such as “about,” “no emesis,” “no significant nausea,” and “therapeutically effective amount.”
Obviousness based on prior use of aprepitant-class NK1 antagonists, palonosetron, and antiemetic combinations.
Anticipation if a prior publication disclosed the same fixed-dose combination, timing, chemotherapy population, and clinical endpoint.
Infringement based on the generic product’s proposed label and dosage instructions.

A Section viii carve-out may reduce risk if the generic label omits the patented chemotherapy-prevention indication. That strategy is difficult if the approved product’s principal commercial use is the patented regimen and the remaining label still directs administration before moderately or highly emetogenic chemotherapy.

Which companies are challenging the Akynzeo patent estate?

Publicly assessable risk is applicant-specific. A Paragraph IV certification does not itself establish an infringement judgment or a launch date. The material questions are:

Which ANDA applicant submitted the certification?
Which Orange Book-listed patents were challenged?
Whether the patent holder filed suit within the Hatch-Waxman 45-day period.
Whether FDA approval was stayed for up to 30 months.
Whether the parties entered a settlement with an agreed launch date.

No final patent invalidity judgment or authorized generic launch is established by the patent claims supplied here. The relevant litigation record must be reviewed across the patent owner, NDA holder, Orange Book-listed patents, and individual ANDA defendants. A settlement, if any, could create an earlier entry date than the December 2030 patent expiration.

How strong is the patent estate for netupitant and palonosetron?

The estate has several layers of potential protection:

Protection layer	Commercial target	Relevance
Composition claims	Netupitant plus palonosetron	Protect the drug combination or pharmaceutical composition
Fixed-dose claims	300 mg/0.5 mg product	Directly targets Akynzeo’s marketed strength
Method-of-use claims	Prevention of chemotherapy-induced nausea and vomiting	Supports label-based infringement theories
Phase-specific claims	Acute, delayed, and overall phases	Creates multiple claim avenues
Outcome claims	No emesis or specified VAS thresholds	Adds clinical-performance limitations
Formulation claims	Capsule, excipients, dissolution, stability	Can block formulation copies
Manufacturing claims	API production or dosage-form manufacture	May create supply-chain barriers

U.S. Patent 9,271,975 is strongest against a generic that copies the approved Akynzeo dose, uses the same pre-chemotherapy timing, and retains the full antiemetic indication. It is weaker against:

Nonoral dosage forms.
Different dosing schedules.
Products that omit the patented indication.
Uses outside chemotherapy-induced nausea and vomiting.
Products using only palonosetron or another NK1 antagonist.
Products that cannot be shown to meet the claimed clinical outcomes.

The patent’s result limitations can narrow enforceability, but they also map closely to the clinical endpoints used in Akynzeo development and FDA labeling. That alignment supports commercial relevance.

How does Akynzeo compare with competing antiemetic products?

Akynzeo combines a neurokinin-1 receptor antagonist, netupitant, with the serotonin 5-HT3 receptor antagonist palonosetron. Its principal alternatives include:

Product or regimen	Principal actives	Competitive position
Akynzeo	Netupitant/palonosetron	Single oral fixed-dose combination
Emend	Aprepitant or fosaprepitant	Established NK1 antagonist franchise
Aloxi	Palonosetron	5-HT3 antagonist, used alone or in combinations
Varubi	Rolapitant	NK1 antagonist with chemotherapy-induced emesis indication
Generic aprepitant	Aprepitant	Lower-cost oral alternative
Olanzapine-based regimens	Olanzapine plus standard antiemetics	Guideline-supported alternative in selected settings

Akynzeo’s patent value comes from combining two pharmacologic mechanisms in one oral product and positioning the dose before chemotherapy for protection across acute and delayed phases. Generic substitution risk is highest from products that replicate both actives and the same dosing instruction.

What licensing deals affect the product?

Netupitant-palonosetron commercialization has involved Helsinn’s product development and regional commercial arrangements. The relevant rights may differ by territory, product presentation, and indication. A license does not change the scope of U.S. Patent 9,271,975 unless the agreement addresses enforcement, patent ownership, or authorized generic rights.

For U.S. diligence, the material commercial-rights questions are:

Whether Helsinn controls the U.S. NDA and patent enforcement.
Whether another company holds U.S. commercialization rights.
Whether an authorized generic arrangement exists.
Whether a settlement grants a third party an agreed launch date.
Whether any license includes patent-challenge restrictions or royalty obligations.

No license term should be inferred from the patent assignment alone. Patent ownership, NDA ownership, and commercial distribution rights can be held by different entities.

What generic launch scenarios exist?

Launch after patent expiration

The cleanest scenario is commercial entry after the projected December 2030 expiration, assuming no patent-term extension or other listed patent remains enforceable.

Launch after Paragraph IV litigation

A generic could launch before expiration if it prevails in litigation, obtains a covenant not to sue, or resolves the dispute on terms permitting entry.

Settlement-based launch

A settlement could authorize entry before December 2030. The entry date may depend on volume limits, royalties, authorized generic rights, or other restrictions.

Section viii carve-out

A generic could seek approval with the patented method of use removed from labeling. This scenario depends on whether the remaining label can be marketed without instructing the patented administration method.

At-risk launch

A company could launch before final resolution. That approach exposes the applicant to damages, injunctive relief, and potential loss of market exclusivity if the patent is upheld.

What geographic coverage does U.S. Patent 9,271,975 provide?

The patent provides protection only in the United States. Parallel patent families may protect netupitant-palonosetron products in Europe, Japan, Canada, and other markets, but foreign claim scope, prosecution history, term, and litigation outcomes differ.

U.S. protection is most relevant to:

U.S. manufacture of the combination.
Importation of the combination into the United States.
U.S. sale or distribution.
U.S. labeling that directs the patented chemotherapy use.
U.S. treatment using the patented regimen.

The patent does not block sales in foreign jurisdictions and does not independently protect manufacturing activity outside the United States unless the resulting product is imported or sold in the United States.

Key Takeaways

U.S. Patent 9,271,975 is a method-of-use patent for oral netupitant plus palonosetron before moderately or highly emetogenic chemotherapy.
Claims 1-7 protect no-emesis and controlled-nausea outcomes across acute, delayed, and overall phases.
Claim 8 directly targets the Akynzeo 300 mg/0.5 mg fixed-dose strength.
Claims 9-12 cover specific chemotherapy agents and dose categories, including carboplatin, cisplatin, anthracyclines, oxaliplatin, and cyclophosphamide.
The projected patent term extends to approximately December 2030.
FDA approval of Akynzeo occurred on October 10, 2014, and regulatory exclusivity expired before the patent term.
Generic risk is highest for an ANDA product using the same dose, oral route, one-hour pre-chemotherapy timing, and full antiemetic indication.
A Section viii carve-out or noninfringement position could reduce exposure but would depend on the proposed generic labeling.
Biosimilar risk is not material because Akynzeo is a small-molecule combination product. The relevant competitors are ANDA-based generic products.
The patent is commercially meaningful but should be evaluated together with Akynzeo’s other Orange Book-listed composition, formulation, dosage, and method-of-use patents.

FAQs

Is U.S. Patent 9,271,975 a composition patent?

No. Its supplied claims are method claims. They require administration of an oral dosage form containing netupitant and palonosetron before emetogenic chemotherapy and require specified clinical outcomes.

Does claim 8 cover every 300 mg netupitant product?

No. Claim 8 depends on claim 1 and retains claim 1’s requirements, including the oral dosage form, administration no more than one hour before chemotherapy, the chemotherapy context, and the no-emesis outcome.

Can a generic omit the Akynzeo indication?

Potentially, through a Section viii labeling carve-out. The result depends on whether the proposed label still instructs use in a manner that falls within the patented method.

Does the patent cover intravenous netupitant-palonosetron therapy?

Not under the supplied claims. Each claim requires an oral dosage form.

Is palonosetron alone covered by U.S. Patent 9,271,975?

No. The claims require both netupitant and palonosetron, or pharmaceutically acceptable salts of those compounds.

References

U.S. Food and Drug Administration. (2014). Akynzeo prescribing information, NDA 205718. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Patent and Trademark Office. (2016). U.S. Patent No. 9,271,975 B2. Washington, DC.
21 U.S.C. § 355. Abbreviated applications and patent certifications.
35 U.S.C. §§ 154, 156. Patent term and patent term extension.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3083	⤷ Start Trial
Australia	2010320598	⤷ Start Trial
Brazil	112012011485	⤷ Start Trial
Canada	2778301	⤷ Start Trial
Chile	2012001276	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,271,975

Which drugs does patent 9,271,975 protect, and when does it expire?

Summary for Patent: 9,271,975